The evaluation of drotaverin intake during pregnancy on fetal development

Research output: Review article

6 Citations (Scopus)


Objective: The safety of drotaverin use during pregnancy is not yet proven, thus the objective of the study was the evaluation of this drug for its effect on fetal development. Method: The dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1991, was analyzed. Results: During the study period, 9.5% of 30 663 pregnant women who had healthy babies (negative control group), 9.4% of 17 300 pregnant women who had babies with congenital abnormalities (index patient group), and 8.0% of 667 pregnant women who had babies with Down's syndrome (positive control group), were treated with drotaverin. The main reasons for drotaverin use were threatened abortion during the second or third month and threatened preterm delivery in the last months of pregnancy. The analysis of index patient-matched control pairs did not show a higher use of drotaverin treatment among mothers of index patients with different congenital abnormality groups. The use of drotaverin was significantly lower in the group of cleft palate. Conclusion: The use of drotaverin had no detectable teratogenic effect.

Original languageEnglish
Pages (from-to)137-145
Number of pages9
JournalPrenatal and Neonatal Medicine
Issue number2
Publication statusPublished - dec. 1 1996

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'The evaluation of drotaverin intake during pregnancy on fetal development'. Together they form a unique fingerprint.

  • Cite this